{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:26:30Z","timestamp":1786980390477,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are few prospective studies of mycophenolate mofetil (MMF) versus cyclophosphamide (CYC) for pediatric lupus nephritis (pLN) and none evaluating rituximab (RTX).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The Prospective Pediatric Lupus Nephritis Registry (ProPeL-R) enrolled patients\u2009&lt;\u200921\u00a0years within 4\u00a0weeks of an initial kidney biopsy diagnostic of pLN. Demographic, clinical, and laboratory data were collected prospectively at enrollment, 3\u00a0months, 6\u00a0months, and then every 6\u00a0months thereafter for up to 5\u00a0years of follow-up. For this study, we compared patients receiving initial therapy with corticosteroids (CS) and either MMF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200933) vs. CYC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918), and those treated with CS, either MMF or CYC, with RTX (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920) vs. without RTX (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200951).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Histology consisted of 18% class III; 35% class IV; 25% mixed class; and 22% pure class V. Eighty-two percent were female. No significant differences in response or infection rates were identified between those receiving MMF or CYC. There was a significant increase in combined complete (CR) and partial response (PR) at 24\u00a0months with RTX use. Overall CR rates at 6 and 24\u00a0months were 35% and 58%, respectively. At 24\u00a0months, 51% of patients continued on CS, and 56% of patients experienced at least one CS side effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MMF and CYC had similar efficacy as initial therapies for pLN. RTX may augment long-term response. However, response rates were suboptimal. Large variations in initial therapy were observed. Given the paucity of prospective data in pLN, our study further illustrates the need for data-driven, pediatric-specific protocols to standardize care and improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-026-07329-z","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:01:44Z","timestamp":1778490104000},"page":"3543-3557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical presentations, treatments, and outcomes of pediatric lupus nephritis: a prospective cohort study from the Pediatric Nephrology Research Consortium"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-297X","authenticated-orcid":false,"given":"Melonie","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Kallash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Rust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia","family":"Jubert-Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Wenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Batisky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana L.","family":"Vasylyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilka","family":"DeJesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome C.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"7329_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 6:7. https:\/\/doi.org\/10.1038\/s41572-019-0141-9","journal-title":"Nat Rev Dis Primers"},{"key":"7329_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00467-020-04686-1","volume":"36","author":"L Oni","year":"2021","unstructured":"Oni L, Wright RD, Marks S, Beresford MW, Tullus K (2021) Kidney outcomes for children with lupus nephritis. Pediatr Nephrol 36:1377\u20131385. https:\/\/doi.org\/10.1007\/s00467-020-04686-1","journal-title":"Pediatr Nephrol"},{"key":"7329_CR3","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1007\/s00467-023-06018-5","volume":"38","author":"C De Mutiis","year":"2023","unstructured":"De Mutiis C, Wenderfer SE, Basu B et al (2023) International cohort of 382 children with lupus nephritis - presentation, treatment and outcome at 24 months. Pediatr Nephrol 38:3699\u20133709. https:\/\/doi.org\/10.1007\/s00467-023-06018-5","journal-title":"Pediatr Nephrol"},{"key":"7329_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"Kidney Disease: Improving Global Outcomes Lupus Nephritis Work G","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes Lupus Nephritis Work Group (2024) KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int 105:S1\u2013S69. https:\/\/doi.org\/10.1016\/j.kint.2023.09.002","journal-title":"Kidney Int"},{"key":"7329_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/acr.25528","volume":"77","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano LR, Askanase A, Bermas BL et al (2025) American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care Res 77:1045\u20131065. https:\/\/doi.org\/10.1002\/acr.25528","journal-title":"Arthritis Care Res"},{"key":"7329_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00467-020-04501-x","volume":"35","author":"A Suhlrie","year":"2020","unstructured":"Suhlrie A, Hennies I, Gellermann J et al (2020) Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. Pediatr Nephrol 35:1235\u20131246. https:\/\/doi.org\/10.1007\/s00467-020-04501-x","journal-title":"Pediatr Nephrol"},{"key":"7329_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/0961203319836712","volume":"28","author":"E Smith","year":"2019","unstructured":"Smith E, Al-Abadi E, Armon K et al (2019) Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus 28:613\u2013620. https:\/\/doi.org\/10.1177\/0961203319836712","journal-title":"Lupus"},{"key":"7329_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1177\/09612033211028658","volume":"30","author":"KM Vazzana","year":"2021","unstructured":"Vazzana KM, Daga A, Goilav B et al (2021) Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort. Lupus 30:1660\u20131670. https:\/\/doi.org\/10.1177\/09612033211028658","journal-title":"Lupus"},{"key":"7329_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE et al (2018) Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93:789\u2013796. https:\/\/doi.org\/10.1016\/j.kint.2017.11.023","journal-title":"Kidney Int"},{"key":"7329_CR10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00467-017-3670-z","volume":"32","author":"E Hessey","year":"2017","unstructured":"Hessey E, Ali R, Dorais M et al (2017) Evaluation of height-dependent and height-independent methods of estimating baseline serum creatinine in critically ill children. Pediatr Nephrol 32:1953\u20131962. https:\/\/doi.org\/10.1007\/s00467-017-3670-z","journal-title":"Pediatr Nephrol"},{"key":"7329_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000339789","volume":"Suppl 2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guidelines for acute kidney injury. Kidney Int Suppl 2:1\u2013138. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Kidney Int"},{"key":"7329_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.semnephrol.2021.09.002","volume":"41","author":"DK Ng","year":"2021","unstructured":"Ng DK, Pierce CB (2021) Kidney disease progression in children and young adults with pediatric CKD: epidemiologic perspectives and clinical applications. Semin Nephrol 41:405\u2013415. https:\/\/doi.org\/10.1016\/j.semnephrol.2021.09.002","journal-title":"Semin Nephrol"},{"key":"7329_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","volume":"99","author":"CB Pierce","year":"2021","unstructured":"Pierce CB, Munoz A, Ng DK, Warady BA, Furth SL, Schwartz GJ (2021) Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int 99:948\u2013956. https:\/\/doi.org\/10.1016\/j.kint.2020.10.047","journal-title":"Kidney Int"},{"key":"7329_CR14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKDWG (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"7329_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1542\/pir.2017-0300","volume":"39","author":"B Viteri","year":"2018","unstructured":"Viteri B, Reid-Adam J (2018) Hematuria and proteinuria in children. Pediatr Rev 39:573\u2013587. https:\/\/doi.org\/10.1542\/pir.2017-0300","journal-title":"Pediatr Rev"},{"key":"7329_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1542\/pir.2023-006017","volume":"45","author":"MC Marsh","year":"2024","unstructured":"Marsh MC, Junquera GY, Stonebrook E, Spencer JD, Watson JR (2024) Urinary tract infections in children. Pediatr Rev 45:260\u2013270. https:\/\/doi.org\/10.1542\/pir.2023-006017","journal-title":"Pediatr Rev"},{"key":"7329_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:1\u201372. https:\/\/doi.org\/10.1542\/peds.2017-1904","journal-title":"Pediatrics"},{"key":"7329_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/acr.21558","volume":"64","author":"R Mina","year":"2012","unstructured":"Mina R, von Scheven E, Ardoin SP et al (2012) Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 64:375\u2013383. https:\/\/doi.org\/10.1002\/acr.21558","journal-title":"Arthritis Care Res"},{"key":"7329_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"7329_CR20","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208\u2013103218. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"key":"7329_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jmii.2023.08.003","volume":"56","author":"HG Chen","year":"2023","unstructured":"Chen HG, Chen JS, Chen YS, Yin CH, Chen HC, Chiou YH (2023) Comparison of mycophenolic acid with cyclophosphamide for the treatment of pediatric lupus nephritis: a retrospective study from a tertiary center hospital in Taiwan. J Microbiol Immunol Infect 56:1105\u20131113. https:\/\/doi.org\/10.1016\/j.jmii.2023.08.003","journal-title":"J Microbiol Immunol Infect"},{"key":"7329_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105600","volume":"86","author":"L Cui","year":"2024","unstructured":"Cui L, Jiao J, Zhang Y et al (2024) FCGR3A-V158F gene polymorphism: a potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 86:105600. https:\/\/doi.org\/10.1016\/j.msard.2024.105600","journal-title":"Mult Scler Relat Disord"},{"key":"7329_CR23","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","volume":"118","author":"SH Lim","year":"2011","unstructured":"Lim SH, Vaughan AT, Ashton-Key M et al (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118:2530\u20132540. https:\/\/doi.org\/10.1182\/blood-2011-01-330357","journal-title":"Blood"},{"key":"7329_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104343","volume":"86","author":"JI Robinson","year":"2022","unstructured":"Robinson JI, Md Yusof MY, Davies V et al (2022) Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. EBioMedicine 86:104343. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104343","journal-title":"EBioMedicine"},{"key":"7329_CR25","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00467-017-3583-x","volume":"32","author":"B Basu","year":"2017","unstructured":"Basu B, Roy B, Babu BG (2017) Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol 32:1013\u20131021. https:\/\/doi.org\/10.1007\/s00467-017-3583-x","journal-title":"Pediatr Nephrol"},{"key":"7329_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00467-017-3767-4","volume":"33","author":"J Hogan","year":"2018","unstructured":"Hogan J, Godron A, Baudouin V et al (2018) Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol 33:111\u2013116. https:\/\/doi.org\/10.1007\/s00467-017-3767-4","journal-title":"Pediatr Nephrol"},{"key":"7329_CR27","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/rheumatology\/keab746","volume":"61","author":"C De Mutiis","year":"2022","unstructured":"De Mutiis C, Wenderfer SE, Orjuela A et al (2022) Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology 61:2563\u20132571. https:\/\/doi.org\/10.1093\/rheumatology\/keab746","journal-title":"Rheumatology"},{"key":"7329_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3899\/jrheum.161554","volume":"45","author":"JE Davidson","year":"2018","unstructured":"Davidson JE, Fu Q, Ji B et al (2018) Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis. J Rheumatol 45:671\u2013677. https:\/\/doi.org\/10.3899\/jrheum.161554","journal-title":"J Rheumatol"},{"key":"7329_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/art.41930","volume":"74","author":"NE Chalhoub","year":"2022","unstructured":"Chalhoub NE, Wenderfer SE, Levy DM et al (2022) International consensus for the dosing of corticosteroids in childhood-onset systemic lupus erythematosus with proliferative lupus nephritis. Arthritis Rheumatol 74:263\u2013273. https:\/\/doi.org\/10.1002\/art.41930","journal-title":"Arthritis & Rheumatology"},{"key":"7329_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s42843-022-00059-4","volume":"48","author":"K Russo","year":"2022","unstructured":"Russo K (2022) Assessment and treatment of adolescents with chronic medical conditions. Journal of Health Service Psychology 48:69\u201378. https:\/\/doi.org\/10.1007\/s42843-022-00059-4","journal-title":"Journal of Health Service Psychology"},{"key":"7329_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3399\/bjgp18X694805","volume":"68","author":"G McGill","year":"2018","unstructured":"McGill G, Ambrose N (2018) The management of lupus in young people. Br J Gen Pract 68:96\u201397. https:\/\/doi.org\/10.3399\/bjgp18X694805","journal-title":"Br J Gen Pract"},{"key":"7329_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/annrheumdis-2011-200106","volume":"71","author":"M Rygg","year":"2012","unstructured":"Rygg M, Pistorio A, Ravelli A et al (2012) A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis 71:511\u2013517. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200106","journal-title":"Ann Rheum Dis"},{"key":"7329_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002752","volume":"9","author":"B Mehta","year":"2023","unstructured":"Mehta B, Jannat-Khah D, Glaser KK et al (2023) Fetal and maternal morbidity in pregnant patients with lupus: a 10-year US nationwide analysis. RMD Open 9:e002752. https:\/\/doi.org\/10.1136\/rmdopen-2022-002752","journal-title":"RMD Open"},{"key":"7329_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/acr.24827","volume":"74","author":"MO Valenzuela-Almada","year":"2022","unstructured":"Valenzuela-Almada MO, Hocaoglu M, Dabit JY et al (2022) Epidemiology of childhood-onset systemic lupus erythematosus: a population-based study. Arthritis Care Res 74:728\u2013732. https:\/\/doi.org\/10.1002\/acr.24827","journal-title":"Arthritis Care Res"},{"key":"7329_CR35","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00467-017-3743-z","volume":"32","author":"M Pereira","year":"2017","unstructured":"Pereira M, Muscal E, Eldin K et al (2017) Clinical presentation and outcomes of childhood-onset membranous lupus nephritis. Pediatr Nephrol 32:2283\u20132291. https:\/\/doi.org\/10.1007\/s00467-017-3743-z","journal-title":"Pediatr Nephrol"},{"key":"7329_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"RA Furie","year":"2020","unstructured":"Furie RA, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"key":"7329_CR37","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070\u20132080. https:\/\/doi.org\/10.1016\/S0140-6736(21)00578-X","journal-title":"Lancet"},{"key":"7329_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","volume":"76","author":"A Saxena","year":"2024","unstructured":"Saxena A, Ginzler EM, Gibson K et al (2024) Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis Rheumatol 76:59\u201367. https:\/\/doi.org\/10.1002\/art.42657","journal-title":"Arthritis Rheumatol"},{"key":"7329_CR39","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP et al (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392:1471\u20131483. https:\/\/doi.org\/10.1056\/NEJMoa2410965","journal-title":"N Engl J Med"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07329-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07329-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07329-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:47:16Z","timestamp":1786978036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07329-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7329"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07329-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board of Ann and Robert H. Lurie Children\u2019s Hospital of Chicago have approved this study, and the corresponding IRB ID is CR00000072.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for conducting this study. Dr. Scott Wenderfer has consultancy agreements to declare with Astra Zeneca, Novartis, and Sobi Canada, but none relate to any of the pharmaceuticals mentioned in the manuscript. All other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}